Emerging preclinical research suggests that GLP-1 receptor agonists may directly inhibit the proliferation of neoplastic cells, promote programmed cell death (apoptosis), and reduce metastatic potential through the regulation of matrix metalloproteinases and their inhibitors
Conditions being studied Scientists are looking at how GLP1 agonists impact: Progression of diabetic retinopathy , a diabetes-related eye disease that can cause blurriness and blindness While initial studies indicated that diabetic retinopathy could worsen while taking this medication, more recent, large-scale data suggests that there is no increased risk
Our guide to managing GLP-1 side effects covers the most effective approaches in detail
doi:10.3390/vaccines14030204 Part 1: Immunosenescence, inflammaging, and the emerging role of vaccine-mediated immunomodulation
I felt my metabolism picking up, and my energy levels soaring
To avoid common pitfalls of stopping GLP-1s, adopt sustained healthy lifestyle habits that will support weight maintenance without the medication